368 related articles for article (PubMed ID: 30902704)
1. Naturally occurring core protein mutations compensate for the reduced replication fitness of a lamivudine-resistant HBV isolate.
Zhang Y; Zhang H; Zhang J; Zhang J; Guo H
Antiviral Res; 2019 May; 165():47-54. PubMed ID: 30902704
[TBL] [Abstract][Full Text] [Related]
2. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene.
Torresi J; Earnest-Silveira L; Civitico G; Walters TE; Lewin SR; Fyfe J; Locarnini SA; Manns M; Trautwein C; Bock TC
Virology; 2002 Jul; 299(1):88-99. PubMed ID: 12167344
[TBL] [Abstract][Full Text] [Related]
3. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants.
Tacke F; Gehrke C; Luedde T; Heim A; Manns MP; Trautwein C
J Virol; 2004 Aug; 78(16):8524-35. PubMed ID: 15280461
[TBL] [Abstract][Full Text] [Related]
4. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B Virus Capsid Assembly Modulators, but Not Nucleoside Analogs, Inhibit the Production of Extracellular Pregenomic RNA and Spliced RNA Variants.
Lam AM; Ren S; Espiritu C; Kelly M; Lau V; Zheng L; Hartman GD; Flores OA; Klumpp K
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559265
[TBL] [Abstract][Full Text] [Related]
6. Identification of hepatitis B virus core protein residues critical for capsid assembly, pgRNA encapsidation and resistance to capsid assembly modulators.
Luo Y; Cheng J; Hu Z; Ban H; Wu S; Hwang N; Kulp J; Li Y; Du Y; Chang J; Viswanathan U; Guo JT
Antiviral Res; 2021 Jul; 191():105080. PubMed ID: 33933516
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus.
Lam AM; Espiritu C; Vogel R; Ren S; Lau V; Kelly M; Kuduk SD; Hartman GD; Flores OA; Klumpp K
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373799
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B Virus Core Protein Dephosphorylation Occurs during Pregenomic RNA Encapsidation.
Zhao Q; Hu Z; Cheng J; Wu S; Luo Y; Chang J; Hu J; Guo JT
J Virol; 2018 Jul; 92(13):. PubMed ID: 29669831
[TBL] [Abstract][Full Text] [Related]
9. In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations.
Wang XY; Wei ZM; Wu GY; Wang JH; Zhang YJ; Li J; Zhang HH; Xie XW; Wang X; Wang ZH; Wei L; Wang Y; Chen HS
Antivir Ther; 2012; 17(5):793-803. PubMed ID: 22668794
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of a novel hepatitis B virus pregenomic RNA encapsidation inhibitor.
Jo E; Ryu DK; König A; Park S; Cho Y; Park SH; Kim TH; Yoon SK; Ryu WS; Cechetto J; Windisch MP
Antiviral Res; 2020 Mar; 175():104709. PubMed ID: 31940474
[TBL] [Abstract][Full Text] [Related]
11. Assembly Properties of Hepatitis B Virus Core Protein Mutants Correlate with Their Resistance to Assembly-Directed Antivirals.
Ruan L; Hadden JA; Zlotnick A
J Virol; 2018 Oct; 92(20):. PubMed ID: 30089690
[TBL] [Abstract][Full Text] [Related]
12. The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
Zhu Y; Curtis M; Borroto-Esoda K
Antivir Chem Chemother; 2011 Aug; 22(1):13-22. PubMed ID: 21860069
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
14. Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy.
Chang UI; Lee YC; Wie SH; Jang JW; Bae SH; Choi JY; Yang JM; Yoon SK; Sun HS
J Med Virol; 2007 Jul; 79(7):902-10. PubMed ID: 17516533
[TBL] [Abstract][Full Text] [Related]
15. Analysis of HBV genotype, drug resistant mutations, and pre-core/basal core promoter mutations in Korean patients with acute hepatitis B.
Lee JH; Hong SP; Jang ES; Park SJ; Hwang SG; Kang SK; Jeong SH
J Med Virol; 2015 Jun; 87(6):993-8. PubMed ID: 25712861
[TBL] [Abstract][Full Text] [Related]
16. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
[TBL] [Abstract][Full Text] [Related]
17. Discovery and Mechanistic Study of Benzamide Derivatives That Modulate Hepatitis B Virus Capsid Assembly.
Wu S; Zhao Q; Zhang P; Kulp J; Hu L; Hwang N; Zhang J; Block TM; Xu X; Du Y; Chang J; Guo JT
J Virol; 2017 Aug; 91(16):. PubMed ID: 28566379
[TBL] [Abstract][Full Text] [Related]
18. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus.
Torresi J
J Clin Virol; 2002 Aug; 25(2):97-106. PubMed ID: 12367644
[TBL] [Abstract][Full Text] [Related]
19. In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication.
Heipertz RA; Miller TG; Kelley CM; Delaney WE; Locarnini SA; Isom HC
J Virol; 2007 Apr; 81(7):3068-76. PubMed ID: 17215289
[TBL] [Abstract][Full Text] [Related]
20. Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure.
Ayres A; Bartholomeusz A; Lau G; Lam KC; Lee JY; Locarnini S
J Clin Virol; 2003 May; 27(1):111-6. PubMed ID: 12727536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
